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The optimal device for heart valve replacement is yet to be devel-
oped. If this is certainly true for adult patients with acquired
pathologies, the need for better materials is even more pressing in
the setting of congenital heart disease, where any valve replacement
activates a ticking clock towards the next procedure.
In this issue of the Journal of Cardiac Surgery, Selcuk et al.1 report
their single‐center experience with the BioIntegral Biopulmonic
Conduit™, implanted as a right ventricle‐to‐pulmonary artery conduit
in 48 pediatric patients over a period of 13 months.1 This is a
stentless porcine heart valve covered with a 10‐cm long porcine
pericardial sleeve, and it is available in relatively small sizes (starting
from 15mm). The conduit is initially treated with formaldehyde and
glutaraldehyde and then detoxified with the No‐React® treatment,
with the aim of reducing the risk of endocarditis and structural
degeneration.2
The No‐React® is just one of several different treatments that
bioprosthesis producers have developed over the last few decades;
all of them released with promises of improved durability, freedom
from structural deterioration, and infection. Despite unquestionable
innovations in engineering and treatment of the available bioma-
terials, with the current technology, surgical reconstruction of the
right ventricular outflow tract (RVOT) in the pediatric population still
exposes patients to a cumulative risk of multiple interventions,
morbidity, and potentially mortality.3
The study by Selcuk et al. is the first to focus on the use of the
BioIntegral Biopulmonic Conduit™ on pediatric patients. The au-
thors' main finding is a high incidence of fever in the early post-
operative period (>30%), not previously described in the literature.
The pathophysiology of the fever in these patients was not clarified.
No clinical or echocardiographic evidence of prosthetic endocarditis
was found in those who experienced fever; however, the authors
point out that this triggered potentially inappropriate antibiotic use
and caused prolonged hospital stay. Furthermore, there seems to be
a correlation between fever and early conduit stenosis.
To put these findings into the correct perspective, a few aspects
must be mentioned. This is a retrospective, single‐center study with
no control group and a relatively small number of patients; the in-
direct evidence that no patient had fever after switching to bovine
jugular vein conduit does not come from a statistical analysis and it
must be considered at best as speculative. Comparison with the
current literature is not straightforward, as the only published paper
focusing on the use of this particular conduit on congenital patients
is the study from Marianeschi et al. from 20014; all previous papers
investigating BioIntegral devices mainly concentrated on midterm
rather than short‐term results.5–9 Finally, the median follow‐up of
14.5 months is short and a trend towards higher gradients in patients
who experienced fever is the only follow‐up information provided by
the authors.
However, other aspects must also be considered, and the au-
thors' concerns regarding the Biopulmonic Conduit™ performance
should not come as a surprise. Even though the literature is highly
heterogeneous in terms of the patient population, the device used,
and study protocols, a few common key points can be identified. This
is not the first study raising questions about early deterioration and
early infection of devices treated with the No‐React® protocol.
Multiple papers focusing on the aortic BioIntegral Bioconduit™ in the
adult population or on similar devices implanted in the pulmonary
position with a long enough follow‐up reported significant rates of
adverse valve‐related events.5–9 Moreover, bioprostheses typically
degenerate earlier in pediatric patients compared to adult patients,
and a similar trend can be expected even in devices undergoing the
No‐React® treatment. This is even more relevant if we consider that
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in the present study, all conduits were implanted in an extra‐
anatomic position (i.e., in a non‐Ross setting), which is a recognized
risk factor for early structural deterioration.10,11 Finally, even if the
fever does not always correlate with infection, it always correlates
with inflammation, which has been strongly linked to structural de-
terioration of bioprostheses.12
Where do we go from here? Better quality research (both pre-
clinical and clinical) in congenital cardiac surgery is needed: a sig-
nificant proportion of our clinical practice still derives from single‐
center experiences and suboptimal observational studies. Outcomes
for the available biological conduits for RVOT reconstruction are
rather unsatisfactory.13–15 This, combined with the limited avail-
ability of small‐size homografts, is the main reason that pushes our
interest towards new devices when they become available. However,
valve replacement in the pediatric age is the ultimate task for any
biomaterial: size, anatomy, and metabolism all plot together against
durability. If there are concerns regarding the performance of a
biomaterial in the adult population, it is very likely that results in
children will be worse.
One may argue that continuing with the current approaches will
only provide small improvements. The future is more likely to come
from development on the use of biomaterials that act as scaffolds,
and which we can repopulate with the patient's own cells. Theore-
tically, this would be expected to improve durability, but also be the
biological substrate for growth, and ultimately reduce morbidity,
reoperations, and mortality. Tissue engineering technologies and
regenerative medicine have expanded considerably over the last
decade, and it may not be long before the translation of this
knowledge into clinical practice.
Regretfully till then, after every pediatric RVOT operation, the
clock will start ticking.
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